



Supernus Pharmaceuticals, Inc.
Investor Relations Department
1550 East Gude Drive
Rockville, MD 20850
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: SUPN

| | |
|---------------|----------------------------|
| Last Trade: | 45.35 |
| Trade Time: | 4:00 PM ET Mar 20, 2018 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 27.80 - 50.05 |
| Volume | N/A |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

Mar 15, 2018

[Supernus Announces Pricing of \\$350 Million Private Offering of 0.625% Convertible Senior Notes](#)

Mar 13, 2018

[Supernus Announces Proposed Private Offering of \\$350 Million of Convertible Senior Notes](#)

Mar 6, 2018

[Supernus to Present at the 2018 Cowen Health Care Conference](#)

Feb 27, 2018

[Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance](#)

Feb 12, 2018

[Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call](#)

Financials & Filings [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 1, 2018

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)